Rusch seeks FDA approval for oesophageal stent
This article was originally published in Clinica
Rusch Inc has submitted its Polyflex oesophageal stent to the US FDA for marketing go-ahead. The company is also about to launch a tracheal version in the US - it was launched in Europe in 1997 (see Clinica No 805, p 13).
You may also be interested in...
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.